<DOC>
	<DOCNO>NCT01589666</DOCNO>
	<brief_summary>This study Phase 1 , single-center , open-label , ascend dose study assess safety tolerability 5 dose spray-dried solvent/detergent treat plasma ( Resusix® ) healthy volunteer .</brief_summary>
	<brief_title>Safety Study Spray-Dried Solvent/Detergent-Treated Plasma Infusion Healthy Volunteers</brief_title>
	<detailed_description />
	<mesh_term>Blood Coagulation Disorders</mesh_term>
	<mesh_term>Hemostatic Disorders</mesh_term>
	<criteria>1 . Subject must provide write informed consent participation study valid contact information . 2 . Subject must male postmenopausal female . 3 . Subject must least 18 year age old 55 year age . 4 . Subject must good general health , significant medical history , clinically significant abnormality physical examination Screening , include history symptom respiratory cardiac disease . 5 . Vital sign within normal limit Screening : 1 . Body temperature within 97°F 99°F 2 . Heart rate 45 100 beat per minute ( bpm ) 3 . Systolic blood pressure ( SBP ) within 90 140 mmHg DBP within 50 90 mmHg . 6 . Subject must normal ( clinically significant abnormality ) EKG Screening prior administration Resusix 1 . PR interval within 120 200 mm/s 2 . QRS interval &lt; 120 mm/s 3 . QTc interval ≤440 mm/s 7 . Subject must laboratory hematology value within follow normal range : 1 . White blood cell count ( WBC ) : 4,500 11,000/mL 2 . Platelet ( PLT ) count : 150,000 400,000/mL ; 3 . Hemoglobin ( Hb ) : 12.5 15.5 g/dL ; 4 . Activated partial thromboplastin time ( aPTT ) : 24.6 36.7 second ; 5 . Normal PT , International Normalized Ratio ( INR ) : 0.8 1.2 ; 6 . Protein C ≥90 % , Protein S ≥77 % ; 7 . Antithrombin III level ( ATIII ) ≥100 % . 8 . Subject must laboratory clinical chemistry value within normal range specify test laboratory . 9 . BMI ≤30 kg/m2 . 10 . Subject must negative toxicology screen panel ( urine test include qualitative identification PCP , barbiturates , THC , amphetamine , benzodiazepine , opiate , cocaine . ) 11 . Subject must nondrinker ( ≤2 alcoholic beverage per week ) nonsmoker ( tobacco product within six month prior Screening ) . 12 . Subject must history recreational ( include IV ) drug use ( selfdeclaration ) . 13 . Subject must ability willingness attend frequent visit study center . 1 . Subject low extremity deep vein thrombosis ( DVT ) Screening . 2 . Subject history coagulopathy thromboembolic disease . 3 . Subject first degree family member history venous thromboembolic disease &lt; 55 year age arterial thromboembolic disease &lt; 45 year age . 4 . Subject documented drug allergy welldescribed reaction . 5 . Subject hepatomegaly , splenomegaly , adenopathy , bruising , and/or ecchymosis identify Screening . 6 . Subject find positive NAT test HIV , HBV HCV . 7 . Subject murmur , rub , gallop cardiac auscultation . 8 . Subject previous transfusion time . 9 . Subject unlikely comply study protocol , opinion investigator , would suitable candidate participation study .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>Entegrion</keyword>
	<keyword>Spray-dried Solvent/Detergent Plasma</keyword>
	<keyword>Fresh Frozen Plasma</keyword>
	<keyword>Transfusion</keyword>
	<keyword>Resuscitation</keyword>
	<keyword>Hemorrhage</keyword>
	<keyword>Coagulopathy</keyword>
</DOC>